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History
Rh is the most well-recognized blood group system 
after ABO because of the immunogenicity of the principal 
antigen, D. Discovered more than 70 years ago, the D 
antigen is well known as the target in severe and potentially 
fatal hemolytic disease of the fetus and newborn (HDFN).1 
Today, HDFN caused by anti-D is much less frequently 
observed in developed countries owing to prevention by 
administration of Rh immunoglobulin (RhIgG; anti-D 
IgG) after delivery of a D+ infant.2,3 Children of women 
of European extraction are more likely affected as D– is 
most common in Caucasians (15–17%), less common in 
African Blacks (3–5%), and uncommon or rare in Asians 
(<0.1%).4 Thus, the D antigen status is not routinely tested 
for in some parts of Asia, principally China, where D– is 
considered a rare blood type. HDFN caused by anti-D is still 
seen where women have limited access to prenatal care and 
in countries where RhIG administration is not standard 
practice. Anti-D during pregnancy is also more often seen 
if RhIG is not administered during the third trimester of 
pregnancy in addition to after delivery. The policy of giving 
antepartum RhIG to all D– women has not been adopted in 
all countries.
The Rh system is a complex RBC antigen system that 
includes more than 50 different antigenic specificities 
(Table 1). “Rh-positive” and “Rh-negative” refer to the 
presence or absence of the D antigen. The five principal Rh 
antigens—D, C, c, E, and e—are responsible for the majority 
of clinically significant antibodies. Some of the others 
represent compound specificities, i.e., ce or f is an epitope 
on the Rhce protein that is not present on RBCs with 
RhcE or RhCe. Many of the antigens are found primarily 
in a population group or specific ethnic group; for example 
CX has the highest prevalence in Finns, and V and VS are 
found primarily in African Black ethnic backgrounds 
(summarized in Reid and Lomas-Francis5).
Our understanding of the Rh system has been greatly 
advanced since the genes were cloned in the early 1990s. The 
sequence of RHCE was first reported in 1990,6,7 and RHD 
was subsequently sequenced in 1992.6,8 The different RHCE 
alleles responsible for the C or c and E or e antigens were 
clarified in 1994.9 In the last decade, molecular genotyping 
has revealed that the genetic diversity of the RH locus 
greatly exceeds estimates predicted by serology. More than 
170 RHD and more than 70 different RHCE alleles have 
been described, and new alleles are still being discovered. A 
directory of RHD alleles is maintained on the RhesusBase 
website, and RHCE alleles are found on the National Center 
for Biotechnology Information (NCBI) human blood group 
mutation Web site.10 In an effort to standardize terminology, 
the International Society of Blood Transfusion (ISBT) 
Working Party on Red Cell Immunogenetics and Blood 
Group Terminology maintains a list of alleles that encode 
blood group antigens (see Web Resources).
Terminology and Nomenclature
The term “Rh” for Rhesus resulted from work by 
Landsteiner and Wiener, who found that antiserum 
produced by immunizing guinea pigs and rabbits with RBCs 
of the Rhesus macaque agglutinated 85 percent of human 
RBCs. Initially, they believed that a common factor “Rh” 
had been identified in animals and humans.11 The antibody 
actually detected the LW antigen, which is present on D+ 
RBCs in greater amounts than on D– RBCs. Although 
misnomers, the terms Rh factor and anti-Rh continued 
in common usage to describe the human D antigen and 
the D antibody. Although the use of “Rhesus” is now 
discouraged, it has been pointed out (WA Flegel, personal 
communication) that “Rh” can be difficult to translate into 
other languages.
Over the years, four Rh system nomenclatures have 
been introduced (Table 1). Terminology established by 
Fisher-Race in England was based on the premise that 
three closely linked genes, C/c, E/e, and D, were responsible 
for the antigens, whereas the Wiener nomenclature (Rh-
Hr) was based on the belief that a single gene encoded 
several blood group factors. The Rh system is encoded 
by two genes, RHD and RHCE, as predicted by Tippett.12 
Rosenfeld gave each Rh antigen a number based on the 
order of its discovery or assignment to the Rh system. The 
ISBT Working Party on Terminology for Red Cell Surface 
Antigens adopted a six-digit number for each RBC antigen.13 
The first three numbers represent the system (the number 
004 was assigned to the Rh system), and the remaining 
three digits refer to the antigenic specificity (Table 1).
Current terminology distinguishes the genes and the 
proteins from the antigens. Capital letters, with or without 
italics, are used when referring to the RH genes, RHD and 
RHCE. Alleles of RHCE are designated after an asterisk, i.e. 
RHCE*ce, RHCE*Ce, RHCE*cE, RHCE*CE, according to 
which antigens they encode. Alleles of RHD are designated 
RHD*DVI, RHD*DIIIa, RHD*weak D type 2, and so on, 
according to the partial or weak D encoded, and the alleles 
have also been given numbers by the ISBT Working Party 
on Red Cell Immunogenetics and Blood Group Terminology 
(see Table 2 for examples and Web Resources). Lastly, the 
Rh proteins are indicated without italics and with the “h” 
in lowercase, as RhD or RhCE, or according to the specific 
antigens they carry, Rhce, RhCe, RhcE, or RhCE.
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Genetics and Inheritance
RH Genes and Rh Proteins
RH genes are inherited as codominant alleles. RHD 
encodes the D antigen and RHCE encodes CE antigens 
(ce, cE, Ce, or CE). Each gene has ten coding exons, and 
the RhD and RhCE proteins differ by 32 to 35 amino acids 
(depending on the specific CE allele). The large number 
of differences explains why D, when seen by the immune 
system of a D– person who lacks the protein, often induces 
a robust immune response. The large number of amino 
acid differences also explains the numerous epitopes of 
the D antigen, estimated to range from 9 to more than 
30.14 Although only nine or ten of the amino acid changes 
are predicted to be on the extracellular surface of the RBC 
membrane, changes located in the transmembrane and 
cytoplasmic regions also alter the topology and epitopes 
of the protein. Although early on it was assumed that only 
extracellular changes would prompt an immune response to 
Rh proteins, new antigens identified by an antibody response 
are also generated with intracellular changes. For example, 
the Leu245Val change in Rhce proteins is not extracellular, 
but this change results in expression of the novel RBC 
antigens V and VS, which are also serologic markers for an 
altered e antigen. Patients who are homozygous for altered 
Rhce alleles encoding partial e antigens type serologically 
as e+, but are at risk for anti-e production when exposed to 
conventional Rhce protein.
The RHCE gene encodes C/c and E/e antigens on a single 
protein. C and c differ by four amino acids, whereas the E 
and e antigens differ by only one amino acid. Although the 
common alleles are RHCE*ce, RHCE*Ce, and RHCE*cE, a 
large number of alleles with additional polymorphisms are 
found in different ethnic groups and are discussed in a later 
section.
Molecular Basis of Rh Antigens
D Antigen
D Negative (Rh-Negative)
Several genetic mechanisms are responsible for the 
D– phenotype, but deletion of the RHD gene is the primary 
background.15 Some exceptions include silenced RHD as a 
result of point mutations, nucleotide insertions, premature 
stop codons, or RHD-CE hybrids. In African Blacks, 66 
percent of D– individuals have a 37-bp insertion in RHD 
causing a premature stop codon, whereas 15 percent carry 
a hybrid RHD-CE-D characterized by expression of weak 
C but no D antigen.16 The rare D– phenotype in Asians is 
often attributable to point mutations in RHD, although 10 
to 30 percent of Asians who type as D– have very low levels 
of D; this phenotype is termed Del.17
D Positive (Rh-Positive)
Most people with D+ RBC phenotypes have 
conventional RhD protein, but more than 150 different 
alleles encoding changes in the amino acid sequence of the 
Table 1.  Rh and RhAG blood group systems: antigen 
terminology/nomenclature
ISBT Rosenfeld Fisher-Race DCE Wiener Other names
Rh
004001 Rh1 D Rh0
004002 Rh2 C rh′
004003 Rh3 E rh″
004004 Rh4 C hr′
004005 Rh5 E hr″
004006 Rh6 ce Hr
004007 Rh7 Ce rhi
004008 Rh8 CW rhW Willis
004009 Rh9 CX rhX
004010 Rh10 V hrV
004011 Rh11 EW rhW2
004012 Rh12 G rhG
Rh13, 14, 15, 16 obsolete
004017 Rh17 Hr0
004018 Rh18 HrS Shabalala
004019 Rh19 hrS Shabalala
004020 Rh20 VS
004021 Rh21 CG
004022 Rh22 CE Rh Jarvis
004023 Rh23 DW Wiel
Rh24 and Rh25 obsolete
004026 Rh26 c-like Deal
004027 Rh27 cE rhi
004028 Rh28 hrH Hernandez
004029 Rh29 Total Rh
004030 Rh30 DCor Gonzalez, Goa
004031 Rh31 hrB Bastiaan
004032 Rh32 RN
004033 Rh33 Har, DHar
004034 Rh34 HrB Bastiaan
004035 Rh35 1114
004036 Rh36 Bea (Berrens)
004037 Rh37 Evans
Rh38 obsolete (see Duclos below)
004039 Rh39 C-like
004040 Rh40 Tar, Targett
004041 Rh41 Ce-like





















030001 RhAG1 Duclos Prev 901013
030002 RhAG2 Ola Prev 700043
030003 RhAG3 DSLK
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protein, or changes in the conserved nucleotides at the ends 
of coding exons required for efficient splicing of pre-mRNA 
to generate mature transcripts, have been reported. These 
result in weak D, partial D, and Del phenotypes.
Weak D
Although common D phenotypes have 10,000 to 
30,000 antigen sites per RBC, weak D RBCs have less 
than 100 to 5000 sites (summarized in Reid and Lomas-
Francis5). Historically, weak D RBCs were defined as 
requiring the IAT for detection, but with the introduction of 
monoclonal antibodies this depends on the specific reagent 
used to test the RBCs. Weak D phenotypes are most often 
associated with single nucleotide changes in RHD.18 These 
encode amino acid changes that negatively affect insertion 
of the protein in the membrane or negatively affect efficient 
splicing of the coding exons, resulting in reduced expression 
of D antigen on the RBCs. To date, more than 70 different 
mutations causing weak D expression have been reported, 
the most common encoding a Val270Gly change called weak 
D type 1.18 The different weak D phenotypes have been given 
number designation, i.e., 1 through 73 to date. (summarized 
by Wagner, FF. RhesusBase Web site; see Web Resources)
Additionally, less D antigen is present in cells that also 
have C antigen, such that an R2R2 individual (DcE/DcE) has 
more D antigen sites than an R1R1 individual (DCe/DCe). A 
weak D phenotype can occur when Ce (r′) is 
present in trans to RHD, and depression of an 
already weak D type by Ce (r′) can result in an 
apparent D– (rr′, r′r′, or r″r′) or Del phenotype 
in a sample that is in reality R (weak D)/r′(Ce).
Del
RBCs with a Del phenotype express very 
low levels of D antigen detected serologically 
only by adsorption and elution with anti-D. 
Del is most commonly found in Asians, who 
comprise 10 to 30 percent of individuals who 
type as D– with standard serologic testing. Del 
is less often found in Europeans (0.027%). In 
Asians, the Del phenotype most often results 
from a nucleotide change 1227G>A, which 
does not affect the amino acid sequence but 
interferes with efficient splicing of exon 9, 
whereas a single amino change, Met295Ile, is 
the most common mutation in Europeans.17,18,19 
Del RBCs are primarily diagnosed by RHD 
genotyping or adsorption and elution studies 
because the RBCs type as D–.
Partial D
RBCs with partial D type serologically 
as D+, but individuals can produce anti-D 
when stimulated by transfusion or pregnancy. 
Because the D antigen consists of numerous conformation-
dependent epitopes (epD), a person who lacks one or 
more D epitopes can form alloantibodies to the missing 
portion(s). More than 30 D epitopes have been defined 
with monoclonal antibodies, designated epD1 through 
epD9 with further subdivisions of each.14 Point mutations 
in RHD causing single amino acid changes, or more often 
hybrid genes in which portions of RHD are replaced by the 
corresponding regions of RHCE, cause partial D. The novel 
sequences of the hybrid protein resulting from regions of 
RhD joined to RhCE result in the loss of D epitopes and 
may generate new low prevalence or cause the loss of high 
prevalence antigens.
Elevated D or D– – Haplotypes
Deletion phenotypes, designated D– –, Dc–, and DCW–, 
(the dashes represent missing antigens) can have enhanced 
expression of D antigen and no, weak, or altered C/c and E/e 
antigens.20 Many are caused by replacement of portions of 
RHCE by RHD, such that the additional RHD sequences in 
RHCE, along with a normal RHD, account for the increased 
D expression. However, some are caused by mutations that 
alter or silence RHCE. For example, a silenced RHCE*cE 
designated RHCE*cE(907del C) encodes a stop codon and 
is associated with the D– – haplotype and the absence of c 
and E antigen expression in Hispanics.21










DIIIa RHD*03.01 186G>T Leu62Phe




DIIIb RHD*03.02 Hybrid with CE exon 2 Ile60Leu
RH:–12 RHD*DIIIb RHD*D-CE(2)-D Ser68Asn
G– Ser103Pro
Weak D example
Type 1 RHD*01W.1 809T>G Val270Gly
RHD*weak D type 1
D– examples




37-bp insert, 609G>A, 
645G>C, 677T>G,  
674C>T, 807T>G
inactive
W in the allele name indicates a weak phenotype.
N in the allele name indicates a null phenotype.
†ISBT Working Party on Red Cell Immunogenetics and Blood Group Terminology
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D and D-like Epitopes on Rhce
One further complication of serologic D status 
determination is the expression of D epitopes by the 
protein product of the RHCE gene in the absence of RHD. 
Two significant examples are DHAR, found in individuals 
of German ancestry,22,23 and Crawford (ceCF), found in 
individuals of African ancestry.24 These two are notable 
because the RBCs show strong reactivity with some 
monoclonal anti-D reagents (3+ to 4+), but are nonreactive 
with others. Other amino acid changes in Rhce mimic 
a D-epitope structure, designated ceSL and ceRT, and 
such RBCs react weakly to some but not all monoclonal 
anti-D.25,26 Importantly, the phenotypes discussed here lack 
the RhD protein, and individuals with them can be readily 
sensitized if transfused with D+ RBCs.22,27
Frequency of Altered RHD
Approximately 2 percent of Europeans carry altered 
RHD, and those most often encountered will vary by 
geographic location, which reflects population diversity in 
the region. In our experience, weak D is found primarily in 
European and Asian backgrounds. The incidence of partial 
RHD alleles in individuals with African backgrounds has 
not been determined but seems to be significantly higher 
than in European populations.
C/c and E/e Antigens
The common RHCE alleles encode the 
C or c and E or e antigens. Of the four amino 
acid changes (Cys16Trp; Ile60Leu; Ser68Asn; 
Ser103Pro) associated with the C to c 
polymorphism, Ser103Pro correlates with C/c 
antigen expression. The E to e polymorphism 
is caused by a single amino acid substitution, 
Pro226Ala. Numerous changes in RHCE cause 
quantitative and qualitative changes in C/c or 
E/e antigen expression, with altered C and e 
most often encountered. More than 70 different 
RHCE alleles are associated with altered, weak, 
or no expression of the principal antigens.
Compound Antigens (ce, Ce, cE, and CE)
Compound antigens define epitopes that 
depend on conformational changes that result 
from amino acids associated with both C/c 
and E/e. These were previously referred to 
as cis products, to indicate the antigens were 
expressed from the same haplotype, but it is 
now known that these are expressed on a single 
protein. These include ce or f, Ce or rhi, cE or 
Rh27, and the rare CE or Rh22. Serologically, 
RBCs with Dce/DCE or DcE/DCe haplotypes 
would be identical when tested with common 
Rh antisera, but only the former sample would 
react with anti-f.
Altered or Variant C and e Antigens
In Caucasians, altered C is not common but when 
encountered is primarily associated with amino acid 
changes Gln41Arg or Ala36Thr, and expression of the CW 
and CX antigens, respectively. RBCs that express CW and 
CX, in the absence of C in trans have weak expression of 
C antigen. Altered C is also associated with RhCE proteins 
expressing novel antigens, including JAHK (Ser122Leu), 
and JAL (Arg114Trp). The RBCs type as C+, but patients 
can make anti-C when exposed to conventional C antigen.
Altered RHCE alleles are relatively common in 
individuals with African ancestry. In this population, the 
most common cause for altered C is an RHDIIIa-CE(4-7)-D 
hybrid gene, which does not encode a D antigen, but encodes 
altered C antigen on a hybrid protein background (Fig. 1). 
Approximately 25 percent of African Americans have this 
hybrid.16 In most cases, the RBCs type C+ with commercial 
monoclonal reagents, and the altered C goes undetected. 
Most of these patients coinherit an altered e antigen and 
have a V–VS+ phenotype; together this haplotype is 
referred to as (C)ceS.28 Because altered RHCE alleles are 
not distinguished by routine serologic tests, homozygous 
patients often make anti-C and anti-e alloantibodies after 
transfusion. Additionally, homozygous individuals typically 
lack high-prevalence antigens, designated hrB and hrS. 
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Table 2B.  Examples of RHCE alleles.† The nucleotides and amino acids 
diagnostic for the presence of RHCE*ce are indicated shaded as the 










RH:4 or c RHCE*c 307C Pro103
RH:5 or e RHCE*e 676G Ala226




RHCE*ce.02 1025C>T Thr342Ile RHCE*ceTI
Ce§ RHCE*02




RH:5 or e RHCE*e 676G Ala226
RH:7 or Ce RHCE*Ce
cE|| RHCE*03 676G>C Ala226Pro
RH:4 or c RHCE*c
RH:5 or e RHCE*E
RH:27 or Ce RHCE*cE
CE** RHCE*04 48G>C Trp16Cys
RH:2 or C RHCE*C 178C>A Leu60Ile
RH:3 or E RHCE*E 203A>G Asn68Ser
RH:22 RHCE*CE 307C>T Pro103Ser
676G>C Ala226Pro
†ISBT Working Party on Red Cell Immunogenetics and Blood Group Terminology.
‡ce=01   §Ce=02   ||cE=03   **CE=04
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Anti-hrB and anti-hrS can be clinically significant,29,30 and 
finding compatible blood can be very difficult because 
of differing RH gene backgrounds.31,32 As an additional 
complication, altered RHCE*ce are often inherited with 
partial RHD (DIII, DAU, DAR, etc.). The inheritance of 
partial D with altered RHCE*ce may lead to production of 
antibodies sometimes identified as anti-HrB (RH34) and 
anti-Hr (RH18).
G Antigen
The G antigen is found on RBCs expressing C or D 
with a 103Ser residue present on RhD, RhCe, or RhCE. 
Serologically, anti-G reacts as though it were anti-D plus 
anti-C. Anti-G explains the D– person transfused with D–
C+ blood, or the D– woman who delivered a D–C+ child, who 
subsequently appears to have made anti-D. To distinguish 
anti-D, -C, and -G, adsorption and elution studies can be 
performed.33 Their results determine the need for RhIG 
prophylaxis for obstetric patients with anti-G to prevent 
additional immunization and formation of anti-D.
Antibodies in the Rh System
Most Rh antigens are immunogenic and have the 
potential to cause clinically significant HDFN or transfusion 
reactions. Rh alloimmunization occurs by exposure to 
foreign RBCs during pregnancy or after transfusion and 
may persist for many years. Even if serum antibody drops 
below detectable levels, subsequent exposure to the antigen 
can produce a rapid secondary immune response. Outside 
of the ABO system, the D antigen is the most immunogenic 
antigen, followed by c and E. Anti-c can cause severe 
HDFN, whereas anti-C, -E, and -e are associated with mild 
HDFN. Because Rh alloimmunization is IgG-mediated, 
transfusion reactions are primarily extravascular. The 
patient may have fever, jaundice, icteric sclera, dark urine, 
or a drop in hemoglobin level. Antigen-negative RBCs 
should be provided to any patient with a history of Rh 
antibody sensitization.
Rh antibodies are often found together. It is not 
unusual for a patient with a single Rh antibody to become 
alloimmunized to additional Rh antigens if further exposed. 
For example, a DCe/DCe (R1R1) patient with anti-E has 
usually been exposed to the c antigen as well. Anti-c may be 
present at the time anti-E is identified, but may be weak and 
undetectable. Therefore, to prevent delayed transfusion 
reactions, some advocate avoiding c+ blood for patients 
alloimmunized to the E antigen. In contrast, pursuing 
anti-E in serum containing anti-c is not necessary as the 
patient will likely have been exposed to c without being 
exposed to E. Moreover, the vast majority of c– donor blood 
will be negative for E.
Rh Antibodies in Patients with Sickle Cell Disease
Some sickle cell transfusion programs perform Rh typing 
to match patients and donors for D, C, and E (in addition to K) 
to prevent alloimmunization.34,35 The prevalence of RH alleles 
that encode altered or variant D, C, and e antigens in African 
ethnic groups often underlies the production of complex Rh 
alloantibody specificities in chronically transfused patients 
with sickle cell disease (SCD). Many altered Rh protein 
epitopes cannot be distinguished serologically, and are 
only identified by RH genotyping once a patient develops 
apparent autoantibodies to Rh antigens. Some common 
examples include the partial C antigen encoded by the r′S 
allele, i.e. (C)ceS, and partial DIIIa; the RBCs react 3+–4+ 
with monoclonal reagents and are not detected as altered. 
Anti-hrS, -hrB, -HrB, and -Hr can be difficult to identify 
and can cause clinically significant hemolytic transfusion 
reactions including transfusion fatalities.30
Other Rh Antibodies
In addition to the SCD population, D– – and Rhnull 
individuals also develop alloantibodies to high-prevalence 
Rh antigens with Rh17 and Rh29 specificity, respectively. 
Lastly, autoantibodies to high-prevalence Rh antigens 
often occur in the sera of patients with warm autoimmune 
hemolytic anemia and in some cases of drug-induced 
autoimmune hemolytic anemia.36 The biologic explanation 
for this apparent specificity or cross-reactivity remains to 
be determined.
Clinical Considerations
Determination of D status
The AABB Standards for Blood Banks and Transfusion 
Services37 requires donor blood to be tested for weak D 
expression and to be labeled as Rh-positive if the test is 
positive. Hospital transfusion services are also required 
to confirm the D-negative status before the unit is 
released for transfusion to avoid transfusion of D+ RBCs 
to D– recipients. It is recognized that some very weak D 
antigens are not detected, and standard typing procedures 
(including IAT) do not detect Del RBCs. Isolated cases have 
been reported in which very weak D and Del donor units 
have caused anti-D alloimmunization in D– recipients.38–41
When determining the D type of a patient, detecting 
weak D expression is not necessary unless testing RBCs of 
an infant of a D– mother at risk for D immunization. DVI 
is the most common partial D found in Caucasians, and 
anti-D produced by women with partial DVI has resulted in 
Figure 1: Representation of the RH gene associated with altered 
C antigen. The RHD and RHCE genes are shown as 10 boxes 
representing the coding exons. Amino acid changes are indicated 
by their single letter designation and the position of the amino acid 
in the protein is given.
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fatal hemolytic disease.42 Therefore, current FDA-licensed 
monoclonal IgM reagents are selected to be nonreactive 
with partial DVI RBCs in direct tests. Performing only a 
direct test and eliminating the indirect test for female 
children and women of child-bearing age avoids the risk of 
sensitization by classifying DVI as D– for transfusion and 
RhIG prophylaxis.
Patients who have RBCs expressing the common type 
1, 2, or 3 weak D phenotype usually do not make anti-D and 
can safely receive D+ blood. Patients with the rare weak 
D types 11 and 15 have become alloimmunized, suggesting 
they have altered D epitopes.38 The risk for anti-D 
production in other uncommon weak D types is unknown. 
In contrast to weak D, patients with partial D RBCs form 
alloanti-D directed at the missing D epitopes and should 
receive D– blood and RhIG when indicated. Unfortunately, 
serologic reagents frequently do not distinguish partial D 
status. Many partial D RBCs, including DIIIa, the most 
common partial D in African Americans, type strongly 
D-positive in direct tests and are only recognized after 
producing anti-D.
Sickle Cell Disease and Altered RH Alleles
RBC alloimmunization remains a serious complication 
of transfusion for patients with SCD, with more than 
25 to 30 percent of chronically transfused SCD patients 
developing RBC antibodies. Altered D, C, and e antigens 
often underlie the complex RH alloantibodies SCD patients 
exhibit after transfusion. Although randomized controlled 
trials have not been performed, extended RBC antigen-
matching (including D, C, E, and K) has been shown in 
numerous single-institutional and prospective multicenter 
experiences to significantly reduce the incidence of alloanti-
body production in SCD.43–45 Therefore, many centers 
determine the pretransfusion RBC serologic phenotype and 
provide RBCs that are antigen-matched for D, C, E, and K. 
Because the high alloimmunization rates are also believed 
to be caused by antigenic disparity between African 
Americans and Caucasians, some programs actively recruit 
African American donors to supply blood specifically for 
patients with SCD.34,35 Although these approaches reduce 
the incidence of alloantibody production, some patients 
still become sensitized to Rh antigens (D, C, e, and hrB, HrB, 
hrS, HrS), indicating they were not Rh antigen matched.
RH Genotyping
RBC genotyping methods were introduced to 
transfusion medicine a decade ago after cloning of the genes 
made genetic testing for blood groups possible. Genotyping 
methods include amplification of target gene sequences by 
PCR followed by analysis using RFLP, real-time PCR, or 
sequence-specific primer PCR. More recently, mass-scale 
genotyping technologies have been developed by several 
manufacturers to perform high-throughput blood group 
prediction.46,47 There is nearly complete concordance 
between the genotype and serologic phenotype, and studies 
have included samples from diverse backgrounds. However, 
the complexities and numerous alleles in the Rh blood 
group system have precluded high-throughput genotyping 
for RH other than for the common nonvariant forms of 
C/c and E/e antigens. The detection of numerous silencing 
mutations is required for accurate typing; several regions 
of the genes must be sampled to detect multiple alleles, and 
new alleles are continuously being identified.48
Currently, RH genotyping is primarily restricted 
to specialized immunohematology laboratories. One 
application of RH genotyping is to find compatible donors in 
the American Rare Donor Program (ARDP) for patients with 
antibodies to high-prevalence Rh antigens.32 Genotyping 
can also be used to determine the RHD status of a fetus by 
amniocentesis or chorionic villus sampling. More recently, 
noninvasive techniques have been used to collect cell-free, 
fetal-derived DNA from maternal plasma for RHD genotype 
prediction with a high-throughput method.49,50 Once high-
throughput platforms encompassing all the Rh variants 
are developed and are cost effective, RH genotyping can 
complement serologic testing for typing transfused patients, 
RHD zygosity determination, fetal D typing, resolution of D 
status, and finding compatible blood for patients with SCD.
RhAG System
RHAG is the ancestral gene from which RHCE and 
RHD arose. It resides on chromosome 6 and encodes the 
Rh-associated glycoprotein and the antigens of the RhAG 
blood group system. The RhAG protein consists of 409 
amino acids and associates with the Rh proteins in the 
membrane to form the Rh-core complex.51
Antigens
The RhAG protein does not express the common Rh 
antigens, but it has recently been shown to carry several 
antigens,52 and it has been assigned system 30 by ISBT 
(Table 1). Two high-frequency antigens, Duclos and 
DSLK, and one low-frequency antigen, Ola, had serologic 
characteristics suggestive of expression on RhAG. This 
was confirmed by gene sequencing and expression of 
recombinant RhAG in HEK 293 cells. The Duclos-negative 
patient was homozygous for a nucleotide 316C>G change, 
encoding Gln106Glu. The DSLK-negative patient was 
homozygous for nucleotide 490A>C, encoding Lys164Gln. 
Two Ol(a+) family members of a Norwegian family were 
heterozygous for 680C>T encoding Ser227Leu. Duclos is 
RHAG1, Ola is RHAG2, and DSLK is provisionally RHAG3.
Rhnull
RhAG protein must be present for the expression of 
Rh antigens. Rhnull RBCs lack expression of Rh antigens, 
and the phenotype most often results from mutations in 
RHAG, previously termed “regulator” Rhnull. Less often, 
Rhnull individuals have inactivating or silencing mutations 
in RHCE and deletion of RHD previously referred to as 
“amorph” Rhnull.33
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The Rh-core complex also interacts with band 3, 
glycophorins A and B, LW, and CD47 and is believed to 
contribute to the RBC membrane structure because Rhnull 
RBCs demonstrate abnormal morphology. The function of 
the Rh blood group proteins is not known, but RhAG is an 
ammonia transporter, and the recent crystalization of the 
human RhAG homolog from the kidney, RhCG, confirms 
the relationship of human Rh proteins to ammonia 
transporters.53
Summary Perspective
The Rh/RhAG blood group systems are some of the most 
complex, and in the past two decades major insights have 
been gained into the molecular basis of the Rh system. The 
genetic information has confirmed many of the predictions 
of the serologists, whose primary (and often only) tools 
were the antibodies made by immunized individuals. 
Exploiting adsorption and elution approaches, along with 
selected RBC testing strategies, they uncovered many of 
the details concerning the specificity and complexity of the 
Rh system. The prediction that Rh antigens are encoded 
by two genes, not one or three, was adeptly forecast by 
Patricia Tippett based solely on serologic observations.12 
Their work is the foundation of our understanding today, as 
new genetic information builds on the serologic backbone. 
Serologic reactivity is still the basis for blood groups and 
blood transfusion practice because serology defines an 
antigen. That will not change as we use DNA-based testing 
methods because it is important to remember that without 
a serologic relationship, a variation in a blood group allele 
at the DNA level is just another SNP (single nucleotide 
polymorphism), and these occur once in every 100 to 300 
bp in the human genome. These polymorphisms are only 
of academic interest until associated with a phenotype and 
found to be relevant to transfusion medicine by stimulation 
of an antibody.
Molecular testing will be a powerful adjunct to serologic 
methods and improve transfusion safety and outcomes, 
particularly for the chronically transfused population. 
Which of the numerous alleles in the Rh system are 
clinically significant is yet to be fully determined. Ultimately, 
with the development of mass-scale RH genotyping 
technology, genetically matching donor units with the 
patients could significantly reduce alloimmunization, and 
RHD genotyping will provide a definitive D classification 
for donors and patients. The availability of cost-effective, 
reliable high-throughput genotyping platforms is needed 
for this to become incorporated into clinical transfusion 
medicine practice.
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